In a pancreatic cancer transgenic mouse model, SFN treatment (50 mg/kg, i.p.)inhibited tumor growth, consistent with the antiproliferative effects of SFN through ROS-activated AMPK signaling pathway and NRF2 nuclear translocation. The gene discussed is NFE2L2; the disease is pancreatic neoplasm.